<span item_type="fundamental" item_id="78c68209b33eec7211e3a7bf23bc8f18" counter_id="ST/US/TNONW" env="prod"></span><span item_type="announcement" item_id="515751309178635009" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 726 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -1.01.</p><p></p><h3>Revenue</h3><ul><li>Revenue for the three months ended March 31, 2025 was $726,000, compared to $719,000 for the same period in 2024, representing a 1% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Cost of Goods Sold, Gross Profit, and Gross Margin</h3><ul><li>Cost of goods sold for the three months ended March 31, 2025 was $403,000, compared to $249,000 for the same period in 2024, representing a 62% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Gross profit for the three months ended March 31, 2025 was $323,000, compared to $470,000 for the same period in 2024, representing a 31% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Gross margin for the three months ended March 31, 2025 was 44%, compared to 65% for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Research and development expenses for the three months ended March 31, 2025 were $691,000, compared to $669,000 for the same period in 2024, representing a 3% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Sales and marketing expenses for the three months ended March 31, 2025 were $1,647,000, compared to $1,381,000 for the same period in 2024, representing a 19% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>General and administrative expenses for the three months ended March 31, 2025 were $1,662,000, compared to $1,926,000 for the same period in 2024, representing a 14% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Loss from Operations</h3><ul><li>Loss from operations for the three months ended March 31, 2025 was -$3,677,000, compared to -$3,506,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Other Income (Expense)</h3><ul><li>Gain on investments for the three months ended March 31, 2025 was $61,000, compared to $27,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Interest expense for the three months ended March 31, 2025 was $0, compared to -$34,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Other expense for the three months ended March 31, 2025 was $0, compared to -$63,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss for the three months ended March 31, 2025 was -$3,616,000, compared to -$3,576,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025 was -$2,483,000, compared to -$2,338,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Net cash used in investing activities for the three months ended March 31, 2025 was $0, compared to -$119,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>Net cash provided by financing activities for the three months ended March 31, 2025 was $6,259,000, compared to $4,371,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>Tenon Medical, Inc. plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund its operations and meet obligations for at least the next 12 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li><li>The company continues to face challenges and uncertainties, including the uncertainty of future revenues from The Catamaran System and changes in business strategy, which may affect its forecasted level of expenditures and use of cash resources.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm"></span></li></ul>

TENON MEDICAL INC C/WTS 16/06/2028 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 726 K